Immunovant to Host Graves’ Disease Program Update on September 9, 2024
Immunovant (Nasdaq: IMVT) has announced an investor webcast scheduled for September 9, 2024, at 8:00 a.m. ET to provide updates on its Graves' Disease (GD) program.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immunovant (Nasdaq: IMVT) has announced an investor webcast scheduled for September 9, 2024, at 8:00 a.m. ET to provide updates on its Graves' Disease (GD) program. The presentation will cover:
- New epidemiologic data on the potential addressable market
- Additional results from the Phase 2 study of batoclimab
- An overview of the IMVT-1402 development program in GD
Investors can register for the event through a provided link, and a live webcast will be available on Immunovant's website. A replay of the event and presentation will be accessible immediately after the webcast concludes.
Details
News Market Reaction – IMVT
The recorded move for IMVT in the trading session of this news was +9.55%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Investor webcast on Monday, September 9th at 8:00 a.m. ET
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Monday, September 9th at 8:00 a.m. ET to provide an update on its Graves’ Disease (GD) program.
The update will consist of new epidemiologic data characterizing the potentially addressable market, additional results from the Phase 2 study of batoclimab, and an overview of the IMVT-1402 development program in GD.
Webcast Details
The company will host a webcast at 8:00 a.m. ET on Monday, September 9th. Please click here to register for the event. The live webcast will also be available under the News & Events section of Immunovant’s website. A replay of the event and presentation will be available immediately following the event.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
Investor Contact:
Renee Barnett, MBA
Chief Financial Officer
Immunovant, Inc.
info@immunovant.com
Source: Immunovant Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.